Sellas Life Sciences is a late-stage biopharmaceutical company developing novel cancer therapeutics, primarily for acute myeloid leukemia and other hematologic and solid tumors. Its two lead candidates are galinpepimut-S (GPS), a peptide immunotherapy targeting the WT1 antigen undergoing Phase 3 testing in AML patients, and SLS009 (tambiciclib), an oral CDK9 inhibitor in Phase 2 development. The company operates on a pre-commercial revenue model generating income through milestone payments and royalties from licensing partners including 3D Medicines and GenFleet Therapeutics, which hold development and commercialization rights in specific territories, while Sellas retains rights outside Greater China and plans to build a specialty oncology sales force upon regulatory approval.